Researchers in Lund, Sweden have been trying to replace the brain cells lost to Parkinson's disease since the 1980s, when the only source was fetal tissue, ethically fraught and impossible to standardize. That effort has continued quietly for four decades, through changing technology and changing ethics, toward a single goal: a manufactured, consistent, scalable source of the same cells. This month, the first peer-reviewed human results from that effort arrived.
THE RADAR
A cell therapy for a currently untreatable form of blindness just passed its first-year mark
At the ISSCR meeting, Cedars-Sinai researchers presented one-year survival data for CNS10-NPC, a neural progenitor cell product injected beneath the retina in 13 patients with retinitis pigmentosa, a group of inherited retinal diseases with no treatment for most patients. The cells survived and the safety profile held up well. Because retinitis pigmentosa can be caused by more than a thousand different genetic mutations, a cell-based approach that doesn't target one specific mutation could in principle help a much broader group of patients than gene therapy alone. The researchers were clear that surviving is not the same as helping: whether these cells actually slow vision loss is the question the next phase of research needs to answer.
A different strategy is taking shape for older spinal cord injuries
Most stem cell research for spinal cord injury targets people in the days or weeks after injury. Researchers at Keio University in Japan presented early data on a different approach built for chronic injuries, where nerve fibers survive but have lost their protective coating. A human trial for this chronic-injury application is planned to begin recruiting in 2027. It has not started yet. Worth watching because most spinal cord injury research targets a narrow early window, leaving chronic patients with few options in development.
Eight Patients, One Year, and What the Data Actually Shows
In Parkinson's disease, the brain gradually loses the nerve cells that produce dopamine, a chemical messenger essential to smooth, controlled movement. As those cells die, symptoms emerge: slowness, stiffness, tremor, a shuffling gait. Current medications replace the missing dopamine chemically, but their effectiveness fades over years, and the side effects grow. Replacing the actual cells, not just the chemical they make, has been the long-standing alternative goal.
On July 9, researchers from Lund University and Skåne University Hospital in Sweden published the first peer-reviewed human results for STEM-PD, a cryopreserved, ready-to-use dopamine progenitor cell product derived from human pluripotent stem cells, in Nature Medicine. This is the first pluripotent stem cell trial approved in Sweden and the first trial of its kind for Parkinson's in Europe.
Eight patients with moderate Parkinson's disease received the cells, transplanted directly into both sides of the brain, at one of two doses, followed by 12 months of immunosuppression to prevent the immune system from rejecting the graft. Seven completed the full year of follow-up. One participant died of a pulmonary infection unrelated to the cell product itself, a reminder that immunosuppression carries its own real risks separate from whatever the transplanted cells do.
The primary goal of the trial was safety, and on that measure, the results were clean. No serious adverse events were linked to the cells. No abnormal movements caused by the graft. No tumor formation, addressing a longstanding theoretical concern with any therapy derived from pluripotent stem cells. Brain imaging using PET scans showed signs the transplanted cells had survived and were active at both six and twelve months.
The efficacy signal is real but needs careful handling. Six of the seven surviving patients substantially reduced their Parkinson's medication over the study period, by roughly 16% in the lower-dose group and 28% in the higher-dose group. Patients in the higher-dose group also reported more good-quality movement time and less time in the "off" state where symptoms return. The researchers flagged an important limitation themselves. Doctors running the trial were permitted to adjust each patient's medication based on clinical judgment throughout the study, and those adjustments weren't always matched by objectively measured improvement in movement scores taken while off medication. That means the medication reductions are a meaningful early signal, not proof the cells alone are driving the benefit.
This is an eight-person, open-label, single-arm study. There was no placebo group and no blinding, both standard and necessary limitations at this stage, and both reasons the results can't yet answer the question of how well this therapy actually works. What they answer is a narrower, earlier question: can this specific manufactured cell product be placed in a human brain safely. The data say yes. The Lund team, along with clinical sites including the University of Cambridge, is continuing long-term follow-up.
WHAT'S REAL / WHAT'S NOISE / WHAT TO WATCH
REAL
Stem cell-derived dopamine cell transplantation for Parkinson's disease has now cleared its first rigorous human safety test, with peer-reviewed data, a completed primary endpoint, and a full year of follow-up. Two independent programs, this one and the autologous approach from Aspen Neuroscience covered previously, are now reporting comparable safety signals using different cell sourcing strategies. That convergence across independent groups adds real weight neither result would carry alone.
NOISE
Any suggestion this trial shows the therapy works. It shows the therapy is survivable and appears safe in a small group over one year. Whether it meaningfully improves symptoms, and for how long, is a question this study wasn't built to answer, and the researchers say so themselves.
WATCH
Long-term follow-up from both the STEM-PD and Aspen programs, and whether a future controlled, blinded trial can separate the effect of the cells from the effect of adjusted medication. That trial is the one that will actually tell us whether this works.
THE RED FLAG REPORT
"Off-the-Shelf" Doesn't Mean "Available"
STEM-PD is described by its own researchers as "off-the-shelf," meaning the cell product can be manufactured in advance and doesn't require a personalized biopsy from each patient. That is a meaningful manufacturing achievement.
It does not mean the therapy is available off any shelf a patient can walk up to. It exists in one completed eight-person safety trial, run by a specific academic and clinical team, under regulatory oversight, using a manufactured product that no commercial clinic can replicate.
Watch for the phrase "off-the-shelf" being used by non-trial providers to suggest ready availability. In this context, it describes a manufacturing method, not a product on any market.
READER LENS
Why researchers can't just "leave the medication alone" during a trial like this
It might seem simple: to know if a cell therapy works, don't change anything else. In practice, that's not how trials involving a serious, symptomatic disease are usually run.
Parkinson's patients experience real day-to-day changes in symptoms and medication needs. An investigator who refuses to adjust medication for a patient in genuine distress, purely to keep the trial data clean, would be putting study design ahead of patient welfare. Most early-phase trials allow clinical judgment for exactly this reason.
The tradeoff is that it becomes harder to say, cleanly, whether an outcome came from the treatment or from a doctor's adjustment made along the way. That's precisely why the STEM-PD researchers flagged their medication-reduction data as an early signal rather than proof, and why the next, larger trial will likely need a placebo-controlled design to sort out the difference.
Forty years ago, doctors in Lund tried the same idea with cells from fetal tissue, one of the most ethically fraught starting points medicine has ever worked with. This year, the same city produced the same idea in a form that can be manufactured, frozen, and shipped. The idea didn't get less difficult. It got more possible.
